InvestorsHub Logo
Followers 34
Posts 1604
Boards Moderated 0
Alias Born 12/12/2013

Re: None

Tuesday, 08/09/2016 8:45:47 AM

Tuesday, August 09, 2016 8:45:47 AM

Post# of 5918
https://www.zacks.com/stock/news/227389/gw-pharma-gwph-reports-narrowerthanexpected-q3-loss

Currently, GW Pharma has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings:
GW Pharma reported a narrower-than-expected loss in the third quarter of fiscal 2016. Our consensus called for a loss of $1.73 per share and the company reported a loss of 73 cents.

Revenues:
However, revenues fell short of expectations. GW Pharma posted revenues of $3.1 million, compared to our consensus estimate of $3.4 million.Key Stats: GW Pharma expects to seek FDA approval for Epidiolex for both Dravet syndrome and LGS indications in the first half of fiscal 2017.